Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  News  >  Economy & Forex

News : Latest News
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors 
All NewsEconomyCurrencies & ForexEconomic EventsCryptocurrenciesCybersecurityPress Releases

Merck adds experimental COVID-19 therapy with OncoImmune deal

11/23/2020 | 06:52am EST
FILE PHOTO: A man wearing a protective face mask walks past an illustration of a virus outside a regional science centre in Oldham

(Reuters) - Merck & Co Inc has agreed to acquire drugmaker OncoImmune in a deal that will give it control of a drug that could help ease symptoms and reduce deaths in patients with severe or critical cases of COVID-19.

Merck is paying $425 million for the private company, in addition to extra payments for regulatory milestones and sales. Merck has built out its portfolio of COVID-19 medicines through a series of deals in recent months, including the acquisition of Australian drugmaker Themis and a partnership with Ridgeback Biotherapeutics LP.

OncoImmune recently announced positive interim data from a phase 3 trial of its leading therapeutic candidate, CD24F, for patients with severe and critical COVID-19.

The data show that the therapy, which is administered as an injection, increased the likelihood of symptom improvement in serious COVID-19 cases and also reduced the risk of respiratory failure and death, said Roger Perlmutter, who heads research at Merck.

He added that CD24F could potentially complement dexamethasone, a generic steroid that is the current standard of care for the most serious COVID-19 cases. The steroid was used to treat U.S. President Donald Trump for COVID-19 in October.

Merck is aiming to develop the manufacturing capacity needed to produce the therapy at scale, which could take weeks to months.

CD24F was originally developed to treat graft versus host disease (GVHD) for patients with leukemia who received stem cell transplants. OncoImmune has initiated phase 3 studies for the drug in GVHD.

Merck is also developing two potential vaccines that are still in early stages of development and an antiviral treatment called molnupiravir.

Pfizer Inc and BioNTech Inc filed for regulatory authorization of their vaccine candidate on Friday after advanced studies show it was highly effective in preventing COVID-19.

(Reporting by Carl O'Donnell, Editing by Rosalba O'Brien)

By Carl O'Donnell


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
BIONTECH SE -0.30% 105.97 Delayed Quote.29.99%
PFIZER INC. -2.87% 36.24 Delayed Quote.-1.55%
Latest news "Economy & Forex"
05:58pCastle Hall Issues Cybersecurity Due Diligence White Paper For Investors, Highlighting Cyber Lessons From 2020
BU
05:57pFACTBOX : Stocks shunned by Wall Street surge as 'GameStop Effect' snowballs
RE
05:53pCommunications Services Down As Investors Retreat From Growth Sectors -- Communications Services Roundup
DJ
05:50pTech Down Amid Mega Cap Earnings Nerves -- Tech Roundup
DJ
05:48pFinancials Down As Wall Street Watches Day Traders Battle Hedge Funds -- Financials Roundup
DJ
05:47pFed Holds Policy Steady as Economy Stumbles -- 4th Update
DJ
05:46pConsumer Cos Down Amid Erratic Trading Of GameStop Shares -- Consumer Roundup
DJ
05:36pHealth Care Down On Risk Aversion -- Health Care Roundup
DJ
05:30pIndustrials Down After Fed Comments, Boeing Earnings -- Industrials Roundup
DJ
05:13pStocks tumble on recovery fears; dollar climbs
RE
Latest news "Economy & Forex"